Hologic, Inc. (NASDAQ:HOLX) Stock Position Lessened by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 261,494 shares of the medical equipment provider's stock after selling 9,658 shares during the period. Principal Financial Group Inc. owned approximately 0.12% of Hologic worth $16,152,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dark Forest Capital Management LP increased its stake in Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 223 shares during the period. Baker Avenue Asset Management LP increased its stake in Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after purchasing an additional 225 shares during the period. EverSource Wealth Advisors LLC increased its stake in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Integrated Advisors Network LLC increased its stake in Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock worth $346,000 after purchasing an additional 289 shares during the period. Finally, J. Safra Sarasin Holding AG increased its stake in Hologic by 4.3% during the fourth quarter. J. Safra Sarasin Holding AG now owns 7,150 shares of the medical equipment provider's stock worth $515,000 after purchasing an additional 293 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Down 1.7%

NASDAQ HOLX traded down $1.13 on Friday, reaching $65.72. The company had a trading volume of 1,776,763 shares, compared to its average volume of 2,391,464. The firm has a market capitalization of $14.65 billion, a PE ratio of 27.73, a P/E/G ratio of 2.41 and a beta of 0.55. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The firm has a 50-day moving average of $61.55 and a 200-day moving average of $63.48. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.03 EPS. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on HOLX shares. Morgan Stanley cut their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and upped their target price for the stock from $60.00 to $80.00 in a research note on Wednesday. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Royal Bank Of Canada cut their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $78.75.

Insider Activity

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director directly owned 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.88% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.